MX2022011692A - Tecnologias para prevenir o tratar infecciones. - Google Patents

Tecnologias para prevenir o tratar infecciones.

Info

Publication number
MX2022011692A
MX2022011692A MX2022011692A MX2022011692A MX2022011692A MX 2022011692 A MX2022011692 A MX 2022011692A MX 2022011692 A MX2022011692 A MX 2022011692A MX 2022011692 A MX2022011692 A MX 2022011692A MX 2022011692 A MX2022011692 A MX 2022011692A
Authority
MX
Mexico
Prior art keywords
preventing
technologies
present disclosure
disclosure provides
treating infections
Prior art date
Application number
MX2022011692A
Other languages
English (en)
Spanish (es)
Inventor
Wayne Charles Widdison
Tomi K Sawyer
Luca Rastelli
David Adam Spiegel
Lawrence Emerson Fisher
Tetyana Berbasova
Alexander Sergei Bayden
Wieslaw Kazmierski
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of MX2022011692A publication Critical patent/MX2022011692A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2022011692A 2020-03-25 2021-03-25 Tecnologias para prevenir o tratar infecciones. MX2022011692A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062994779P 2020-03-25 2020-03-25
US202063001455P 2020-03-29 2020-03-29
US202063055860P 2020-07-23 2020-07-23
PCT/US2021/024186 WO2021195401A1 (en) 2020-03-25 2021-03-25 Technologies for preventing or treating infections

Publications (1)

Publication Number Publication Date
MX2022011692A true MX2022011692A (es) 2023-02-09

Family

ID=77890439

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011692A MX2022011692A (es) 2020-03-25 2021-03-25 Tecnologias para prevenir o tratar infecciones.

Country Status (12)

Country Link
US (1) US20230330240A1 (https=)
EP (1) EP4125893A4 (https=)
JP (1) JP2023520188A (https=)
KR (1) KR20220158762A (https=)
CN (1) CN115697415A (https=)
AU (1) AU2021244228A1 (https=)
BR (1) BR112022018945A2 (https=)
CA (1) CA3176256A1 (https=)
IL (1) IL296725A (https=)
MX (1) MX2022011692A (https=)
PH (1) PH12022552499A1 (https=)
WO (1) WO2021195401A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159372A1 (en) 2021-01-22 2022-07-28 Decoy Therapeutics, Inc. Methods and compositions for treating infections
WO2023150375A2 (en) * 2022-02-07 2023-08-10 Decoy Therapeutics Inc. Methods and compositions for treating covid infections
CN116440285A (zh) * 2023-04-19 2023-07-18 山西锦波生物医药股份有限公司 冠状病毒多肽类融合抑制剂的长效化的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3069986A1 (en) * 2017-07-26 2019-01-31 Kleo Pharmaceuticals, Inc. Universal abt compounds and uses thereof

Also Published As

Publication number Publication date
US20230330240A1 (en) 2023-10-19
BR112022018945A2 (pt) 2022-12-13
JP2023520188A (ja) 2023-05-16
CA3176256A1 (en) 2021-09-30
EP4125893A4 (en) 2024-10-16
EP4125893A1 (en) 2023-02-08
KR20220158762A (ko) 2022-12-01
PH12022552499A1 (en) 2024-03-25
IL296725A (en) 2022-11-01
AU2021244228A1 (en) 2022-11-17
WO2021195401A1 (en) 2021-09-30
CN115697415A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
ZA202301437B (en) Compounds and methods for treatment of viral infections
PH12022551441A1 (en) Diacylglycerol kinase modulating compounds
PH12022552499A1 (en) Technologies for preventing or treating infections
MX2024010591A (es) Compuestos y metodos para el tratamiento de infecciones virales.
MX2020012416A (es) Anticuerpos dirigidos contra il-33 y sus usos.
MX2021010528A (es) Metodos y composiciones para el tratamiento de las ulceras.
MX2016007533A (es) Composiciones y metodos para el suministro fagocitico de agentes anti-estafilococicos.
BR112015013123A2 (pt) inibidores de beta-lactamase
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
SA523440384B1 (ar) مركبات الفوسفوليبيدات واستخداماتها
WO2019209948A8 (en) Compounds and uses thereof
EA202092748A1 (ru) Модуляторы экспрессии apol1
EA201991650A1 (ru) Способы лечения неврологических расстройств
ZA202006612B (en) Antibacterial compounds
WO2022046922A3 (en) Antibody molecules that bind to nkp30 and uses thereof
MX2021004114A (es) Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.
PH12016500465A1 (en) Deoxynojirimycin derivatives and methods of their using
MX2021015448A (es) Células linfocíticas activadas y métodos para usarlas para tratar cáncer y afecciones infecciosas.
CL2019001918A1 (es) Métodos para tratar infecciones bacterianas.
WO2022170155A3 (en) Technologies for preventing or treating infections
MX2026002369A (es) Compuestos antivirales y metodos de elaboracion y uso de los mismos
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
CR20240365A (es) Compuestos antivirales y métodos de elaboración y uso de los mismos
MX2022003814A (es) Compuestos antibacterianos de 4-quinolinona.
MX2022003816A (es) Compuestos antibacterianos.